Novartis CEO: AI Could Cut Drug Development Time by Years
Reported by Fierce Biotech, Bloomberg and Crypto Briefing3 sources ↓
Novartis CEO Vasant Narasimhan says AI could reduce drug-development time from 12 years to eight and improve the odds of bringing candidates to market. He says the company already uses AI in clinical trials, data analysis and drug discovery.
Key points
- Novartis aims to raise the success rate for first-in-human drug candidates from 8% to 12%, Crypto Briefing reports
- AI-assisted discovery has shortened candidate selection from three to four years to about 18 to 24 months, Crypto Briefing reports
- About 90% of Novartis development content is AI-assisted, Crypto Briefing reports
Sources
Details
In his interview with Bloomberg’s Francine Lacqua, Narasimhan said AI is helping Novartis run clinical trials faster, analyze data and identify drug candidates. He also sits on Anthropic’s board.
Crypto Briefing reports that AI platforms can simulate thousands of trial enrollments in minutes, compared with weeks previously. The outlet also reports a 25% reduction in clinical study report timelines and says statistical programming for 2026 trials is 90% faster; it notes that many of these efficiency figures are internal and do not establish that drugs will pass later trials or regulatory review faster.
Written from coverage as of
Images
- Crypto Briefing
Stocks in this story
Change since open: 20 Nov to 21 Nov 2026
Last refresh